Trends and Racial Differences in the Use of Androgen Deprivation Therapy for Metastatic Prostate Cancer April P. Carson, PhD, Daniel L. Howard, PhD, William R. Carpenter, PhD, Yhenneko J. Taylor, MS, Sharon Peacock, MS, Anna P. Schenck, PhD, Paul A. Godley, MD, PhD Journal of Pain and Symptom Management Volume 39, Issue 5, Pages 872-881 (May 2010) DOI: 10.1016/j.jpainsymman.2009.09.013 Copyright © 2010 Terms and Conditions
Fig. 1 Proportion of men receiving LHRH agonists, orchiectomy, or no ADT, by diagnosis year for African-American and white men with metastatic prostate cancer, SEER-Medicare 1991–1999. Journal of Pain and Symptom Management 2010 39, 872-881DOI: (10.1016/j.jpainsymman.2009.09.013) Copyright © 2010 Terms and Conditions
Fig. 2 Probability of receipt of ADT during months following diagnosis by race, SEER-Medicare 1991–1999. Journal of Pain and Symptom Management 2010 39, 872-881DOI: (10.1016/j.jpainsymman.2009.09.013) Copyright © 2010 Terms and Conditions
Fig. 3 Proportion of men treated with an orchiectomy or an LHRH agonist by race, among those receiving ADT, SEER-Medicare 1991–1999. Journal of Pain and Symptom Management 2010 39, 872-881DOI: (10.1016/j.jpainsymman.2009.09.013) Copyright © 2010 Terms and Conditions